Acadia Pharmaceuticals Inc.

This study tests the long-term safety of an experimental drug, ACP-204, for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). About 752 adults aged 55 to 95 who completed a prior ACP-204 study will take the drug for 52 weeks. Researchers will …

This study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a prior study will receive the spray three times daily. The main goal is to mo…

This study tests a drug called ACP-204 for people with Lewy body dementia who experience psychosis (hallucinations or delusions). Over 52 weeks, researchers will monitor safety and side effects in 126 adults who previously completed an earlier phase of the trial. The goal is to s…

This study tests a nasal spray called carbetocin to help control the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 170 people aged 5 to 30 will receive either the spray or a placebo for 12 weeks. The main goal is to see if the spray reduces food-seek…